<?xml version='1.0' encoding='utf-8'?>
<document id="14691574"><sentence text="Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype."><entity charOffset="30-43" id="DDI-PubMed.14691574.s1.e0" text="acenocoumarol" /><entity charOffset="48-58" id="DDI-PubMed.14691574.s1.e1" text="diclofenac" /><entity charOffset="60-68" id="DDI-PubMed.14691574.s1.e2" text="naproxen" /><entity charOffset="73-82" id="DDI-PubMed.14691574.s1.e3" text="ibuprofen" /><pair ddi="false" e1="DDI-PubMed.14691574.s1.e0" e2="DDI-PubMed.14691574.s1.e0" /><pair ddi="false" e1="DDI-PubMed.14691574.s1.e0" e2="DDI-PubMed.14691574.s1.e1" /><pair ddi="false" e1="DDI-PubMed.14691574.s1.e0" e2="DDI-PubMed.14691574.s1.e2" /><pair ddi="false" e1="DDI-PubMed.14691574.s1.e0" e2="DDI-PubMed.14691574.s1.e3" /><pair ddi="false" e1="DDI-PubMed.14691574.s1.e1" e2="DDI-PubMed.14691574.s1.e1" /><pair ddi="false" e1="DDI-PubMed.14691574.s1.e1" e2="DDI-PubMed.14691574.s1.e2" /><pair ddi="false" e1="DDI-PubMed.14691574.s1.e1" e2="DDI-PubMed.14691574.s1.e3" /><pair ddi="false" e1="DDI-PubMed.14691574.s1.e2" e2="DDI-PubMed.14691574.s1.e2" /><pair ddi="false" e1="DDI-PubMed.14691574.s1.e2" e2="DDI-PubMed.14691574.s1.e3" /></sentence><sentence text="NSAIDs are reported to increase the risk of bleeding in coumarin users"><entity charOffset="56-64" id="DDI-PubMed.14691574.s2.e0" text="coumarin" /></sentence><sentence text=" The mechanism underlying this risk is inhibition of platelet aggregation, however a pharmacokinetic mechanism resulting in an increased International Normalised Ratio (INR) was proposed in some case reports in warfarin treated patients" /><sentence text=" In this retrospective cohort study the influence of diclofenac, naproxen and ibuprofen on the INR of outpatients stabilised on acenocoumarol therapy was investigated"><entity charOffset="53-63" id="DDI-PubMed.14691574.s4.e0" text="diclofenac" /><entity charOffset="65-73" id="DDI-PubMed.14691574.s4.e1" text="naproxen" /><entity charOffset="78-87" id="DDI-PubMed.14691574.s4.e2" text="ibuprofen" /><entity charOffset="128-141" id="DDI-PubMed.14691574.s4.e3" text="acenocoumarol" /><pair ddi="false" e1="DDI-PubMed.14691574.s4.e0" e2="DDI-PubMed.14691574.s4.e0" /><pair ddi="false" e1="DDI-PubMed.14691574.s4.e0" e2="DDI-PubMed.14691574.s4.e1" /><pair ddi="false" e1="DDI-PubMed.14691574.s4.e0" e2="DDI-PubMed.14691574.s4.e2" /><pair ddi="false" e1="DDI-PubMed.14691574.s4.e0" e2="DDI-PubMed.14691574.s4.e3" /><pair ddi="false" e1="DDI-PubMed.14691574.s4.e1" e2="DDI-PubMed.14691574.s4.e1" /><pair ddi="false" e1="DDI-PubMed.14691574.s4.e1" e2="DDI-PubMed.14691574.s4.e2" /><pair ddi="false" e1="DDI-PubMed.14691574.s4.e1" e2="DDI-PubMed.14691574.s4.e3" /><pair ddi="false" e1="DDI-PubMed.14691574.s4.e2" e2="DDI-PubMed.14691574.s4.e2" /><pair ddi="false" e1="DDI-PubMed.14691574.s4.e2" e2="DDI-PubMed.14691574.s4.e3" /></sentence><sentence text=" We also determined the role of cytochrome P450 2C9 (CYP2C9) polymorphism on coumarin dosage and INR in NSAID users"><entity charOffset="77-85" id="DDI-PubMed.14691574.s5.e0" text="coumarin" /></sentence><sentence text=" The study was carried out at the Groningen Outpatient Thrombosis Service" /><sentence text=" A retrospective cohort study among patients who received both acenocoumarol and one of the NSAIDs under study was performed"><entity charOffset="63-76" id="DDI-PubMed.14691574.s7.e0" text="acenocoumarol" /></sentence><sentence text=" Patients whose INR rose above the upper level of the therapeutic range (INR above 3" /><sentence text="5 or 4" /><sentence text="0) after an NSAID under study was added to the acenocoumarol therapy, were compared with patients who did not show such an elevation"><entity charOffset="47-60" id="DDI-PubMed.14691574.s10.e0" text="acenocoumarol" /></sentence><sentence text=" A two-sample t-test (average acenocoumarol dosage, age), and chi-square tests (sex, therapeutic range, type of NSAID) were used to test for differences" /><sentence text=" Genotyping was carried out by analysing blood samples for the relevant CYP2C9 alleles" /><sentence text=" The study population consisted of 112 patients on stable acenocoumarol therapy, of which 52 (46%) showed an elevation of the INR above the desired therapeutic level (INR 3"><entity charOffset="58-71" id="DDI-PubMed.14691574.s13.e0" text="acenocoumarol" /></sentence><sentence text="5 and 4" /><sentence text="0 respectively) after the start of an NSAID under study" /><sentence text=" In 12 patients, the INR increased above 6" /><sentence text=" The INR of the other 60 patients (54%) remained constant after the start of one of the NSAIDs under study" /><sentence text=" There were no statistically significant differences between patients with increased INR and patients without increased INR with regard to age, sex, therapeutic range and average acenocoumarol dosage" /><sentence text=" Eighty patients, of whom 36 showed an increased INR as a result of a potential acenocoumarol-NSAID drug interaction, were included in the genotyping study" /><sentence text=" No association between CYP2C9 genotype and an increased INR as a result of the drug-drug interaction was found" /><sentence text=" In nearly half of a cohort of elderly patients, the INR increased beyond the therapeutic range (INR 3" /><sentence text="5 or 4" /><sentence text="0) as a result of a potential pharmacokinetic drug-drug interaction between acenocoumarol and diclofenac, naproxen and ibuprofen"><entity charOffset="76-89" id="DDI-PubMed.14691574.s23.e0" text="acenocoumarol" /><entity charOffset="94-104" id="DDI-PubMed.14691574.s23.e1" text="diclofenac" /><entity charOffset="106-114" id="DDI-PubMed.14691574.s23.e2" text="naproxen" /><entity charOffset="119-128" id="DDI-PubMed.14691574.s23.e3" text="ibuprofen" /><pair ddi="false" e1="DDI-PubMed.14691574.s23.e0" e2="DDI-PubMed.14691574.s23.e0" /><pair ddi="false" e1="DDI-PubMed.14691574.s23.e0" e2="DDI-PubMed.14691574.s23.e1" /><pair ddi="false" e1="DDI-PubMed.14691574.s23.e0" e2="DDI-PubMed.14691574.s23.e2" /><pair ddi="false" e1="DDI-PubMed.14691574.s23.e0" e2="DDI-PubMed.14691574.s23.e3" /><pair ddi="false" e1="DDI-PubMed.14691574.s23.e1" e2="DDI-PubMed.14691574.s23.e1" /><pair ddi="false" e1="DDI-PubMed.14691574.s23.e1" e2="DDI-PubMed.14691574.s23.e2" /><pair ddi="false" e1="DDI-PubMed.14691574.s23.e1" e2="DDI-PubMed.14691574.s23.e3" /><pair ddi="false" e1="DDI-PubMed.14691574.s23.e2" e2="DDI-PubMed.14691574.s23.e2" /><pair ddi="false" e1="DDI-PubMed.14691574.s23.e2" e2="DDI-PubMed.14691574.s23.e3" /></sentence><sentence text=" The average increase in INR was between 1 and 4" /><sentence text=" Polymorphism of CYP2C9 does not seem to be a relevant risk factor for the NSAID-acenocoumarol interaction" /><sentence text="" /></document>